Sorrento Therapeutics Inc (SRNE)

[dia76ca]

I don't know who prepares this list but it is always interesting.
"Sorrento Therapeutics Boom List
1. Covi-Stix approved in Mexico- June 2021- Expecting large revenues, Brazil and US to follow.
2. ACEA owned- full ownership of Abivertinib, multiple pipeline additions and a large manufacturing facility.
3. License Partner, Kelun, Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers released positive results Jun 21.
4. Q1 2021 results show strong revenue growth and swing in to profit!
5. COVI-MSC- Phase 1b tests complete 10/10 patients recovered from mechanical ventilation and leaving hospital after a week!!! Phase 2 PIVOTAL Approved in Brazil May 2021
6. Sofusa DoseConnect multiple Ph1b trials Jan 2021. Drug already approved – this is all about the delivery. Results started May 2021 and were very positive. Multiple drugs can be dosed this way and used to extend patents! June 2021 1b trial delivery patients with Melanoma- first of many with Mayo C.
7. ANP Acquisition nearing completion will open Sorrento to significant advances in testing
8. COVISHIELD Ramping up development in partnership with Mount Sinai. This will speed up the development of combination antibody along with STI-2020 to combat the SA variant with higher efficacy. Sorrento will licence multiple antibodies and pay in stock subject to FDA approval milestones.
9. Lee’s Pharmaceutical Anti-PD-L1 Antibody Socazolimab, licensed from Sorrento ph3 approval in China. Not only treats Lung cancer, trials planned for other types. Approval in China could open Sorrento to expedited approval elsewhere.
10. Fortune Bio (Sorrento Manufacturer in China) Confirmed Covi-Stix being made with CE approval certificate. This and Respi-Stix listed for sale. http://www.fortunetest.com/. Setting up manufacturing in US and moving Fortune Bio Technology to fulfil this (believed to be pre requisite for FDA approval and Government Contract. Confirmed in a job description. “ready to produce tens of millions per month” -Ji
11. RESPI-STIX patent applied for Jan 16 to create combination test for antibody and current viruses including Covid, Flu A and B – Manufacturing at Zhengzhou Fortune Bioscience Co
12. Covi-Trace application submitted- Brunswick mentioned they are submitting a low nasal swab version
13. Last year we acquired multiple companies. We own 25% of Celulatory who are listing for approx. $2bn due to merger with GX Acquisition Corp
14. STI-6643 Ph1 Trial approved for multiple cancer type treatments “Basket Trial”
15. Sorrento Therapeutics entered into an Exclusive Licensing Term Sheet with Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome- Ph2 already approved to proceed
16. Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Haematological Malignancies and Solid Tumours Based on an Exclusive Technology License from the Mayo Clinic- Multiple IND’s in 2021- April 2021 FDA Clearance to Proceed with Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma
17. DARPA funding of at least $34m to bring STI 2020 to the end of P2 trials and beyond. Three phase 2 trials of COVI-AMG being delivered to 1000 patients. STI2020 is a refined version of 1499 with increased potency and requires smaller dosage.
18. Abivertinib - Cures Covid at late stages. Stage 2 trials complete results soon. Ji hinted test are over 50% success. Israel announced they have repurposed a cancer drug with similar positive response.
19. Institutions buying in and own 28% of stock: BlackRock 6% Vanguard 5% and State Street 3.5%
20. Covi-Drops STI2099 (Refined version of 1499) nasal antibody spray kills all Covid in early stages and can be administered in doctors surgery, maybe at home. PH1b FDA approved March 2. PH2 trial in the UK
21. 11 Covid programs in progress with strong potential- Vaccines removed from pipeline to focus on these, however T-VIVIA-19 could come back to beat mutations if others fail.
22. Multiple cancer and pain relief plays which triggered BO offers of $7 a year ago before we started developing for Covid.
23. Yes, we only have one drug approved (ZTildo) but sales are growing massively
24. Immunity Bio and NK merger completed resulting in us owning 8.19m shares in the new company $IBRX. PSS is chairman of NK making it more likely our Cynviloq case has been settled. Expecting $1bn in stock or cash as part of the settlement. Our stake at launch $317m+
25. Four analysts have us at $20-35 which is very conservative.
26. Testing Lab approved in California for Covid (will speed up in house testing and provide source of revenue)
27. CEO only gets share options if he maintains SP above $17-130 for six consecutive months
28. We have been heavily shorted due to a scam by Hindenburg (top 30 most shorted) and now we are poised for a massive short squeeze.
29. SP-102 Ph3 trial results-potentially the first FDA approved ..."